Sphingolipid Metabolism and Leukemia: A Potential for Novel Therapeutic Approaches
Journal:
Anti-Cancer Agents in Medicinal Chemistry
Volume:
11
Page:
863-881
Author(s):
Tara Ann Burns and Chiara Luberto
Sphingolipid Metabolism and Drug Resistance in Hematological Malignancies
Journal:
Anti-Cancer Agents in Medicinal Chemistry
Volume:
11
Page:
891-903
Author(s):
Valerie Gouaze-Andersson and Myles C. Cabot
Editorial [Hot Topic: Overview of Antiangiogenic Therapies in Hematological Malignancies (Guest Editor: D. Ribatti)]
Journal:
Current Cancer Drug Targets
Volume:
11
Page:
995-996
Author(s):
D. Ribatti
Cytokines as Anti-Angiogenic Agents in Haematological Malignancies
Journal:
Current Cancer Drug Targets
Volume:
11
Page:
997-1004
Author(s):
C. Cocco, E. Ferretti, I. Airoldi and V. Pistoia
Emerging Therapies Targeting Tumor Vasculature in Multiple Myeloma and other Hematologic and Solid Malignancies
Journal:
Current Cancer Drug Targets
Volume:
11
Page:
1005-1024
Author(s):
K. Podar and K. C. Anderson
Anti-Angiogenic Therapies in the Treatment of Waldenstrom's Macroglobulinemia
Journal:
Current Cancer Drug Targets
Volume:
11
Page:
1025-1029
Author(s):
A. Sacco, I. M. Ghobrial and A. M. Roccaro
Antiangiogenesis in Myelodysplastic Syndrome
Journal:
Current Cancer Drug Targets
Volume:
11
Page:
1044-1052
Author(s):
A. Aguayo, F. M. Armillas-Canseco and D. Martinez-Banos
Clinical Experience with Antiangiogenic Therapy in Leukemia
Journal:
Current Cancer Drug Targets
Volume:
11
Page:
1053-1068
Author(s):
J. Wellbrock and W. Fiedler
The Pros and Cons of Targeting Protein Kinase c (PKC) in the Management of Cancer Patients
Journal:
Current Pharmaceutical Biotechnology
Volume:
12
Page:
1961-1973
Author(s):
F. Coluccio Leskow, M. A. Krasnapolski and A. J. Urtreger
Exploitation of Apoptosis Pathways for Childhood Leukemia
Journal:
Current Pediatric Reviews
Volume:
7
Page:
266-270
Author(s):
Simone Fulda